<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Reports of Biochemistry and Molecular Biology</title>
<title_fa></title_fa>
<short_title>rbmb.net</short_title>
<subject>Basic Sciences</subject>
<web_url>http://rbmb.net</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2322-3480</journal_id_issn>
<journal_id_issn_online>2322-3480</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/rbmb</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1395</year>
	<month>2</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2016</year>
	<month>5</month>
	<day>1</day>
</pubdate>
<volume>4</volume>
<number>2</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Construction of a Novel DNA Vaccine Candidate Encoding an HspX-PPE44-EsxV Fusion Antigen of Mycobacterium tuberculosis</title>
	<subject_fa>زیست شناسی ملکولی</subject_fa>
	<subject>Molecular Biology</subject>
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;em&gt;&lt;strong&gt;Background:&lt;/strong&gt;&lt;/em&gt; &lt;em&gt;Mycobacterium tuberculosis&lt;/em&gt; is the causative agent of tuberculosis (TB). &lt;em&gt;Bacille Calmette-Guerin&lt;/em&gt; (BCG) vaccine, is not effective in adults, therefore, many efforts have been made to produce an effective adult TB vaccine. The aim of this study was to develop a new tuberculosis DNA vaccine candidate encoding a recombinant HspX-PPE44-EsxV fusion antigen of &lt;em&gt;M. tuberculosis. &lt;/em&gt;&lt;/p&gt;

&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;em&gt;&lt;strong&gt;Methods:&lt;/strong&gt;&lt;/em&gt; A fusion DNA segment consisting of HspX, linker, PPE44, linker, and EsxV, after codon optimization, was designed. The fusion DNA was cloned and its sequence confirmed. Then, expression of a recombinant pcDNA3.1 (+)/HspX-PPE44-EsxV plasmid in Chinese hamster ovary (CHO) cells was verified by RT-PCR and Western-blot analysis.&lt;/p&gt;

&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;em&gt;&lt;strong&gt;Results:&lt;/strong&gt;&lt;/em&gt; A 1968 bp band in RT-PCR and a 68 kDa band on Western-blot analysis confirmed transcription and expression of recombinant &lt;em&gt;hspX-ppe44-esxV&lt;/em&gt; in eukaryotic cells.&lt;/p&gt;

&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;em&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;&lt;/em&gt;A recombinant DNA segment encoding the HspX-PPE44-EsxV fusion antigen of &lt;em&gt;M. tuberculosis&lt;/em&gt; was constructed and considered to be tested as a new TB DNA vaccine candidate.&lt;/p&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>DNA vaccine, EsX, Hsp, Mycobacterium tuberculosis, PPE44</keyword>
	<start_page>89</start_page>
	<end_page>97</end_page>
	<web_url>http://rbmb.net/browse.php?a_code=A-10-1-55&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Bagher </first_name>
	<middle_name></middle_name>
	<last_name>Moradi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>10031947532846006137</code>
	<orcid>10031947532846006137</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Mojtaba </first_name>
	<middle_name></middle_name>
	<last_name>Sankian</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>10031947532846006138</code>
	<orcid>10031947532846006138</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Yousef </first_name>
	<middle_name></middle_name>
	<last_name>Amini</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>10031947532846006139</code>
	<orcid>10031947532846006139</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Zahra </first_name>
	<middle_name></middle_name>
	<last_name>Meshkat</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>meshkatz@mums.ac.ir</email>
	<code>10031947532846006140</code>
	<orcid>10031947532846006140</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
